Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label vaccine. Show all posts
Showing posts with label vaccine. Show all posts
Saturday, May 26, 2012

not yet recruiting: Cyclophosphamide and Vaccine Therapy in Treating Patients With Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

›
Cyclophosphamide and Vaccine Therapy in Treating Patients With Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - ...
Tuesday, April 24, 2012

phase 2/UK: The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer - Full Text View - ClinicalTrials.gov

›
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer - Full Text View - ClinicalTrials.gov The Activity of Tro...

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

›
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovaria...
Sunday, April 22, 2012

For whom the bell tolls at Prima Biomed - CVac ovarian cancer vaccine

›
For whom the bell tolls at Prima Biomed "Prima is developing a treatment for ovarian cancer and, at 22¢, its market capitalisation ...
Thursday, March 22, 2012

ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh - MarketWatch

›
ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh - MarketWatch ImmunoCellular The...
Wednesday, January 25, 2012

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission - Full Text View - ClinicalTrials.gov

›
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Per...
Wednesday, January 18, 2012

The Oncologist: Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer (prospective single site study + 2 related articles))

›
Blogger's Note: reminder - full access requires subscription ($$$); note also related articles   Abstract   Background. The immune...
Wednesday, December 28, 2011

Canadian researchers close in on vaccine for ovarian cancer - media

›
Canadian researchers close in on vaccine for ovarian cancer
Wednesday, August 17, 2011

press release: Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines

›
ROCHESTER, Minn. — Mayo Clinic has received investigational new drug approval ( http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprova...
Monday, July 18, 2011

Future Medicine - Immunotherapy (IL-17)- Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer Full Text

›
Wednesday, June 22, 2011

financial news: Immunovaccine Nominates Brad Thompson for Appointment to the Board - DepoVax™

›
Brad Thompson, Ph.D., is Executive Chairman, Chief Executive Officer and President of Oncolytics Biotech Inc. and is the current Chairman of...

media: FDA OKs clinical trials for cancer vaccine (DPX-Suvivac)

›
"In the trials of DPX-Suvivac, ovarian cancer patients will be treated with the vaccine after surgery and chemotherapy treatments....

press release: Hemispherx Biopharma's Ampligen(R) Tested in Combination With Experimental Vaccine (Dr. George Coukos/vaccine/ovarian)

›
Friday, April 15, 2011

PR-USA - Immunovaccine Reports Positive Interim Data from Phase I Clinical Trial of DPX-0907 in Patients With Ovarian Cancer

›
"....The ongoing Phase I clinical trial of DPX-0907 is an open-label, dose-escalating evaluation of the vaccine's safety and toler...
Monday, February 21, 2011

Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial -- SYDNEY, Feb. 18, 2011 /PRNewswire/ --

›
"......The trial will be conducted on 750 patients in a double blind placebo controlled study randomized 1:1 of CVac vs. Standard of C...
Wednesday, January 26, 2011

clinical trial: Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

›
Purpose The purpose of this research study is to collect tumor samples at the time of surgery and store them for possible use as p...
Monday, June 07, 2010

Editorial free full access: Conflicts of interest and pandemic flu -- Godlee 340: c2947 -- BMJ

›
Monday, May 31, 2010

Clinic claims vaccine represents a breast cancer breakthrough

›
Monday, April 05, 2010

abstract: pre-clinical - A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses - DepoVax

›
DepoVax
Saturday, April 03, 2010

Merck KGaA - EU regulator calls for review of Erbitux (cetuximab) / cancer vaccine Stimuvax (BLP25 liposome vaccine)

›
Safety concerns:  1) Erbitux (cetuximab) 2) cancer vaccine Stimuvax (BLP25 liposome vaccine)